Bellevue Group AG Takes Position in Zai Lab Limited (NASDAQ:ZLAB)

Bellevue Group AG purchased a new stake in Zai Lab Limited (NASDAQ:ZLAB - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 13,000 shares of the company's stock, valued at approximately $340,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Pictet Asset Management Holding SA purchased a new position in shares of Zai Lab in the 4th quarter valued at about $31,000. Barclays PLC grew its position in shares of Zai Lab by 337.6% in the fourth quarter. Barclays PLC now owns 3,702 shares of the company's stock valued at $97,000 after purchasing an additional 2,856 shares during the last quarter. US Bancorp DE raised its position in shares of Zai Lab by 1,671.9% during the 4th quarter. US Bancorp DE now owns 5,865 shares of the company's stock worth $154,000 after purchasing an additional 5,534 shares during the last quarter. Townsquare Capital LLC purchased a new stake in Zai Lab in the 4th quarter valued at approximately $243,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Zai Lab by 15.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,061 shares of the company's stock worth $290,000 after acquiring an additional 1,502 shares during the last quarter. Institutional investors and hedge funds own 41.65% of the company's stock.

Zai Lab Trading Up 2.8 %

NASDAQ:ZLAB traded up $0.78 during mid-day trading on Thursday, hitting $29.14. The company had a trading volume of 828,066 shares, compared to its average volume of 868,357. Zai Lab Limited has a 1 year low of $16.01 and a 1 year high of $39.77. The firm has a market capitalization of $3.21 billion, a price-to-earnings ratio of -10.52 and a beta of 1.04. The business has a fifty day simple moving average of $32.90 and a 200-day simple moving average of $29.76.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.12). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. As a group, research analysts anticipate that Zai Lab Limited will post -2.58 earnings per share for the current year.

Analyst Ratings Changes

ZLAB has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Zai Lab in a report on Thursday, March 27th. Scotiabank assumed coverage on Zai Lab in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price objective for the company. Bank of America reiterated a "neutral" rating and set a $36.10 target price (up from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd. Finally, JPMorgan Chase & Co. increased their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a report on Thursday, March 13th.

Insider Buying and Selling

In other news, CEO Ying Du sold 50,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.44, for a total transaction of $1,622,000.00. Following the transaction, the chief executive officer now directly owns 494,117 shares in the company, valued at $16,029,155.48. The trade was a 9.19 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Yajing Chen sold 5,280 shares of Zai Lab stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.89, for a total value of $189,499.20. Following the sale, the chief financial officer now owns 25,471 shares of the company's stock, valued at approximately $914,154.19. This represents a 17.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 138,744 shares of company stock worth $4,685,294 in the last three months. 13.88% of the stock is currently owned by insiders.

Zai Lab Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.